Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Period	PE Ratio
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	-6.01
2020-12-31	N/A
2021-12-31	3.29
2022-12-31	13.53
2023-12-31	-5.47
2024-12-31	-3.81
2025-12-31	-205.60

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OMER	$10.28	+6.64%	2.63M
3
4
5

Omeros Corporation (OMER) PE Ratio

PE Ratio Data

Get Omeros Corporation Data in Excel

More OMER Financial Data